ADVERTISEMENT

404

Not Found

Is this what you were looking for?

tag stock market disease medicine

DNA molecule.
Finding DNA Tags in AAV Stacks
Mariella Bodemeier Loayza Careaga, PhD | Mar 7, 2024 | 8 min read
Ten years ago, scientists put DNA barcodes in AAV vectors, creating an approach that simplified, expedited, and streamlined AAV screening. 
Taking Stock
Clare Kittredge(ckittredge@the-scientist.com) | Mar 13, 2005 | 6 min read
When Human Genome Sciences in Rockville, Md., recruits top scientists, the biotechnology company usually offers them a stake in its future success in the form of stock options.
a photo of the packaging for the drug Trikafta
FDA Approves New Cystic Fibrosis Drug
Shawna Williams | Oct 24, 2019 | 1 min read
The treatment, Trikafta, increases lung function in most patients with the disease—but comes with a hefty price tag.
Special Report
Surgisphere Sows Confusion About Another Unproven COVID-19 Drug
Catherine Offord | Jun 16, 2020 | 10+ min read
The company behind a now-discredited study on hydroxychloroquine also posted a report that has been cited by Latin American governments recommending ivermectin as a possible coronavirus treatment. Clinicians there say the effects have been extremely damaging.
The Protean Job Market
Ted Agres | Sep 15, 2002 | 6 min read
Image: Erica Johnson Life scientists looking for work can take heart in the fertile job market despite worldwide economic doldrums: Jobs exist in plenty and should remain abundant for some time. Nevertheless, some market trends make it trickier now to snag a high-paying position than in recent years. Venture capitalists reluctant to risk investments in biotechnology have pressured small and midsize companies to reduce expenses and bring products to market more quickly. Also, mergers and consol
Economics limits availability of drugs to treat parasitic diseases
John Borchardt | Nov 12, 2000 | 4 min read
Many drugs effective against tropical diseases are no longer available or in danger of being pulled from the market because they are unprofitable.
Pet Meds Adapted from Human Therapies
Jenny Rood | Oct 1, 2016 | 8 min read
Companies focused on developing treatments for dogs, cats, and horses are bringing a diverse array of products to the pet medicine market.
FDA Approves Gene Therapy for Spinal Muscular Atrophy
Ashley Yeager | May 27, 2019 | 3 min read
At $2 million for a single dose, Novartis’s Zolgensma is the most expensive medicine to date, but still less expensive over a lifetime than another approved drug for the rare genetic disease.
Predicting Future Zoonotic Disease Outbreaks
Ashley Yeager | Jun 1, 2018 | 10+ min read
A step-by-step study of diseases that jump species gives subtle clues about future epidemics.
Opinion: Share Data for All Diseases
Elizabeth Marincola | Apr 28, 2016 | 2 min read
Along with his recent $250 million donation to cancer research, Silicon Valley entrepreneur Sean Parker emphasized the importance of data sharing.

Run a Search

ADVERTISEMENT